Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.
Insulin resistance is characterized as one of the major pathogeneses of type 2 diabetes and has been associated with these same cardiovascular risk factors. Troglitazone, rosiglitazone, and pioglitazone are a new class of oral antidiabetic agents which can ameliorate peripheral insulin resistance in type 2 diabetes. There is considerable evidence that trogliterazone may have beneficial effects on cardiovascular and metabolic abnormalities associated with insulin resistance. There is supportive evidence for positive effects of the other glitazones, but they have been less well studied. These potential benefits span effects ranging from molecular events in the arterial wall to amelioration and/or improvement in lipid parameters known to be associated with atherosclerosis.
Horikoshi
H
H
Sankyo Pharma Research Institute, La Jolla, CA 92037, USA.
Hashimoto
T
T
Fujiwara
T
T
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D002302:Cardiac Output / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002839:Chromans / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D014280:Triglycerides / Q000097:blood; D000077288:Troglitazone
D002839:Chromans; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D013844:Thiazoles; D045162:Thiazolidinediones; D014280:Triglycerides; D002784:Cholesterol; D000077288:Troglitazone